VEC-162 20 mg + Placebo + VEC-162 50 mg
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Insomnia
Conditions
Primary Insomnia
Trial Timeline
Nov 1, 2007 → Jun 1, 2008
NCT ID
NCT00548340About VEC-162 20 mg + Placebo + VEC-162 50 mg
VEC-162 20 mg + Placebo + VEC-162 50 mg is a phase 3 stage product being developed by Vanda Pharmaceuticals for Primary Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT00548340. Target conditions include Primary Insomnia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00548340 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Insomnia